EGF and non-small cell lung carcinoma: During the preparation of this article, Kim et al. reported that gefitinib, a first-generation reversible TKI, inhibits EGF-stimulated intracellular Ca2+ oscillations in non-small-cell lung cancer cells and that restricting extracellular Ca2+ can consequently enhance gefitinib sensitivity [24].